

News from CureGN

Sponsored by the NIH/NIDDK

December 2015

Thank you for your time and contributions to CureGN. Please find below some updates about this important, one-of-a-kind study.

What is the purpose of CureGN?

The Cure Glomerulonephropathy Network (CureGN) is a first of its kind, five-year study of patients with kidney diseases that damage the small filtering units of the kidney (glomeruli) and cause protein and/or blood to leak into the urine.

The study includes adults and children with minimal change disease, focal segmental glomerulosclerosis (FSGS), membranous nephropathy, and immunoglobulin A (IgA) nephropathy.

This study includes a larger number of patients and plans a longer follow-up than any other study of these uncommon kidney diseases. 2400 patients are being invited from over 60 centers in the US, Canada, and Italy to help with this effort to gather enough patient data to finally make much needed progress towards a cure.

The study aims to better understand why people get these diseases, how they respond to therapy, and to support research to find better ways to diagnose, treat, and predict outcomes of these diseases.

www.curegn.org

Enrollment


...

Clinical research studies like CureGN depend on you!

As of 11/09/2015:

Enrolled: 856

Goal: 2400





Patient Resource - NephCure Kidney International

NephCure Kidney International is a supporter of CureGN. NephCure is committed to support research and life-changing therapies to treat, and ultimately cure, the major kidney diseases included in CureGN. NephCure grassroots events like Walks, Community Events, and Nephletes generate the funds and awareness that will help make the goal of cure a reality. NephCure also runs the NephSpace online support community. Patients, caregivers, family members, and friends are welcome to connect with other members of the kidney disease community through these resources. Check us out at www.nephcure.org

Thank you for participating in CureGN, a five-year study funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. Your involvement will help researchers better understand a group of kidney diseases that accounts for about 10 percent of people who receive dialysis in the U.S.

As there are no specific therapies for many glomerular kidney diseases, the NIDDK brought together researchers to study adults and children who have minimal change disease, focal segmental glomerulosclerosis (FSGS), membranous nephropathy, and IgA nephropathy. Knowing more about the diseases ultimately will help researchers identify potential targets for treatment which, we hope, will spark pharmaceutical company interest in working with CureGN investigators to develop new therapies.

We could not do this study without your help. By joining CureGN you are helping to move science forward and offering hope to many more people and families affected by glomerulonephritis. We look forward to making discoveries together.

Sincerely,

Michael F. Flessner, MD, PhD

Marva Moxey-Mims, MD

Division of Kidney, Urologic,
and Hematologic Diseases



CureGN Sites Around the World